Get carefully chosen free stock picks based on a detailed technical analysis.
In finance, technical analysis is a security analysis discipline for forecasting the direction of prices through the study of past market data, primarily price and volume. Don't forget to Subscribe to get regular updates.
Company Description The Estee Lauder Companies Inc. is a manufacturer and marketer of skin care, makeup, fragrance and hair care products. Its products are sold in over 150 countries and territories under a number of brand names, including Estee Lauder, Aramis, Clinique, Origins, M.A.C, Bobbi Brown, La Mer and Aveda. It is also the global licensee for fragrances and/or cosmetics sold under brand names, such as Tommy Hilfiger, Donna Karan, Michael Kors, Sean John and Coach. These channels include over 30,000 points of sale, consisting of department stores, specialty retailers, upscale perfumeries and pharmacies and prestige salons and spas. In addition, its products are sold in freestanding Company-operated stores, its own and authorized retailer Websites, stores on cruise ships, direct response television, in-flight and duty-free shops and certain fragrances are sold in self-select outlets. During the fiscal year ended June 30, 2011, it acquired the license to develop Ermenegildo Zegna products.
Faizan's take EL last traded at $101.70 a share. The stock has good upward momentum which I anticipate will continue for a few more months at the least. Price target $117.00 (15% gain).
Company Description Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company. Regeneron discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. As of December 31, 2010, the Company had one marketed product: ARCALYST (rilonacept) injection for subcutaneous use, which is available for prescription in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. Its late stage programs are VEGF Trap-Eye (aflibercept ophthalmic solution), which is being developed for the prevention and treatment of serious eye diseases; ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment, and aflibercept (VEGF Trap), which is being developed in oncology in collaboration with the sanofi-aventis Group.
Faizan's take REGN closed at $65.2 a share on Friday. This stock has a lot of momentum on its side, and can make a decent up move in the next couple of months. Price target $74 (12.8% gain).
NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points.
Company Description MasterCard Incorporated (MasterCard) is a global payments company that provides a economic link among financial institutions, businesses, merchants, cardholders and governments worldwide, enabling them to use electronic forms of payment instead of cash and checks. The Company provides a variety of services in support of the credit, debit, prepaid and related payment programs of approximately 22,000 financial institutions and other entities that are its customers. The Company offers payment solutions, which enable its customers to develop and implement credit, debit, prepaid and related payment programs for their customers, which include cardholders, businesses and government entities. MasterCard manages a family of payment card brands, including MasterCard MasterCard, Maestro and Cirrus, which the Company license to its customers. MasterCard generates revenue by charging fees to its customers for providing transaction processing and other payment-related services.
Faizan's take Mastercard (MA) last traded at $339.10 a share. The stock looks technically sound. Just today it broke an ascending triangle formation on good volume, indicating a bull run in the near mid term. Suggested price target $384.00 (13.2% gain).
NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points.
Company Description Silver Wheaton Corp. (Silver Wheaton) is a mining company, which generates its revenue primarily from the sale of silver. As of December 31, 2010, Silver Wheaton had entered into 14 long-term silver purchase agreements and two long-term precious metal purchase agreements. The Company operates in nine business segments: the silver produced by the San Dimas, Zinkgruvan, Yauliyacu, Penasquito, Cozamin, Barrick and Other mines, the gold produced by the Minto mine and corporate operations. Its wholly owned subsidiaries include Silver Wheaton (Caymans) Ltd. and Silverstone Resources (Barbados) Corp. In December 2010, Silver Wheaton sold its La Negra silver interest to Aurcana Corporation (Aurcana). On May 21, 2010, the Company acquired Ventana Gold Corp. (Ventana). On November 3, 2010, it acquired Bear Creek Mining Corporation (Bear Creek).
Faizan's take On Friday SLW closed at $40.71. Its chart pattern is demonstrating good technical health. I expect this stock to continue its upward move during the next 6 -12 month period. Suggested price target $48.00 (17.9% gain).
NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points
Company Description Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market, as well as for application in its biothreat, industrial, and partner markets. The company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company’s systems integrate these steps and analyze complex biological samples in its proprietary test cartridges.
Faizan's take CPHD traded at $31.13 a share on Monday's close. Its chart is showing a perfectly formed head and shoulder topping pattern. Shorting CPHD today might yield a good profit in the near mid term. Suggested price target $28.55 (8.3% gain).
NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points.
Company Description Lentuo International Inc. is a holding company. The Company is a non-state-owned automobile retailer in Beijing, the People's Republic of China. As of June 30, 2010, it operated six franchise dealerships, 10 automobile showrooms, one automobile repair shop and one car leasing company in the Beijing metropolitan area. It provides a one-stop shop experience for its customers by offering them a range of automobile products and services in each of its franchise dealerships (4S dealerships). 4S stands for sales, spare parts, services and survey, and its dealerships offer a range of automobile retail services. The Company offers passenger vehicles, auto parts and accessories for sale, as well as automobile repair and maintenance services, and provide a channel for vehicle manufacturers to gather customer feedback.
Faizan's take LAS last closed at $5.68 a share. The chart is demonstrating good technicals and the stock may give a decent profit within the next 6 months. Suggested price target $6.89 (21% gain).
NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points.
Company Description Corinthian Colleges, Inc. (Corinthian) is a post-secondary education company in the United States and Canada, serving the segment of the population seeking to acquire career-oriented education. As of June 30, 2010, the Company had a student enrollment of 110,580 and operated 101 schools in 25 states, and 17 schools in the province of Ontario, Canada. As of August 13, 2010 all of its schools operated under one of three national brands, Everest, WyoTech, or Heald. As of June 30, 2010, 101 out of 118 schools were operating under the Everest brand, six schools were operating under the WyoTech brand, and 11 schools were operating under the Heald brand. The Company offers a variety of diploma programs and associate's, bachelors and master's degrees through a single operating segment. Its training program areas include healthcare, criminal justice, mechanical, trades, business and information technology. On January 4, 2010, the Company completed its acquisition of Heald Capital, LLC.
Faizan's take Corinthian Colleges Inc. (COCO) yesterday closed at $5.06 a share. My analysis of this stock shows that after a one year long downtrend now might be the time when COCO starts moving up. It can be expected to a fair degree of confidence that a good upward trend will be established soon and will continue for a few months. Suggested price target $6.97 (37% gain).
NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points.
Company Description Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. The company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Each of these product candidates is a combination of generic drugs, which it has systematically screened for synergistic central nervous system, or CNS, activity. Each of the components of its product candidates has already received regulatory approval and has been commercialized previously.
Faizan's take OREX last closed at $3.34 a share. Recently it broke out of a well formed symmetric triangle. It has potential to give a decent profit within the next year. Suggested price target $4.47 (34% gain).
NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points
"UPDATE: As of 1st June 2011 I will just name my picks with a little company information. Background technical analysis for each stock will not be provided anymore. This is because writing detailed technical analysis is very time consuming which my busy schedule does not allow.
Instead I will like to promote discussions in the comments section and would like to listen to your take on the recommended picks.
However, if you still want the background analysis feel free to ask in the comments section or through email."
Company Description
Agilysys, Inc. is a leading provider of innovative IT solutions to corporate and public-sector customers, with special expertise in select markets, including retail and hospitality. The company develops technology solutions — including hardware, software and services — to help customers resolve their most complicated IT needs. The company possesses expertise in enterprise architecture and high availability, infrastructure optimization, storage and resource management, and business continuity, and provides industry-specific software, services and expertise to the retail and hospitality markets. Headquartered in Solon, Ohio, Agilysys operates extensively throughout North America, with additional sales offices in the United Kingdom and in Asia. Agilysys has three reportable segments: Hospitality Solutions Group (“HSG”), Retail Solutions Group (“RSG”), and Technology Solutions Group (“TSG”).
Faizan's take
Currently trading at $6.81 a share AGYS has potential to leap upto 20% in value over the next 6 months or so. Suggested price target is $8.29 (21% gain).
NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points.
"UPDATE: As of 1st June 2011 I will just name my picks with a little company information. Background technical analysis for each stock will not be provided anymore. This is because writing detailed technical analysis is very time consuming which my busy schedule does not allow.
Instead I will like to promote discussions in the comments section and would like to listen to your take on the recommended picks.
However, if you still want the background analysis feel free to ask in the comments section or through email. "
Company Description Companhia de Bebidas das Américas—AmBev is the successor of Companhia Cervejaria Brahma (“Brahma”) and Companhia Antarctica Paulista Indústria Brasileira de Bebidas e Conexos (“Antarctica”), two of the oldest brewers in Brazil. Antarctica was founded in 1885. Brahma was founded in 1888 as Villiger & Cia. The Brahma brand was registered on September 6, 1888, and in 1904 Villiger & Cia. changed its name to Companhia Cervejaria Brahma. AmBev, a Brazilian sociedade anônima, was incorporated as Aditus Participações S.A. (“Aditus”) on September 14, 1998. AmBev is a publicly held corporation incorporated under the laws of the Federative Republic of Brazil.
Faizan's take
ABV currently at $31.54 is demonstrating very good technicals and can give a decent profit in the upcoming months. Suggested price target is $33.89 (7.5% increase).
NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points.
Interphase Corp. (INPH) is a technology company which specializes in computer peripherals. As of now it is trading at $5.20 a share. Interesting formations are appearing on INPH's chart which I would like to point out.
The following chart is a daily chart for INPH with an Ichimoku cloud overlay.
First thing to notice on this chart is that starting May 2009 INPH established a continuous downtrend which finally lasted in November 2010. During this 19 month time period the stock lost more than 80% of its value. At that time the stock was highly oversold, and was ready for a good upthrust.
Then, starting December 2010 the stock made some rapid upward moves and after about 1.5 years it finally broke above the Ichimoku cloud on incredibly high volume. Supporting this increase was a sharp uptrend in the stock's RSI which is a very bullish indicator. Also, at the tip of this uptrend the stock broke a very significant resistance level at $6.00 leaving no overhead resistance on this 3 year chart. This clearly shows that the current tape formation for this chart is very healthy and we can expect a continued upward trend for the near short term.
Now lets look at another chart for INPH.
This is a one year daily chart without the Ichimoku overlay. On this chart we can see that after the recent high at around $6.50 the stock is now trading in a narrow symmetric range. A breakout above this range will indicate another bullish run, while a breakdown would mean a correction. So this chart is worth keeping an eye on as well.
Also, notice that recently the 50 day and the 200 day moving averages crossed over indicating a bull. Combined with that the Chaikin Money Flow indicator shows that the stock has remained above the crucial zero line for most of the last six months indicating that the stock is fueled up now and is ready for a ride. (For more on volume indicators read The Trader's Book of Volume: The Definitive Guide to Volume Trading).
Finally to decide on good sell points we shall take a look at the following all data chart for INPH.
It can be seen from this chart that the next resistance level(from 2007) is around $9.00-$10.00. So, this can be a good sell point for mid term traders. This is just a casual advice. Rely on your own intellect to choose a sell point, because finding a good sell point is more of an art than science.
(Being a pure technician I usually avoid listening to news about stocks. But going against my own beliefs I would like to throw in one: Interphase Corp's directors Strunk Christopher, and Myers Michael collectively purchased 9000 shares of INPH on 15th and 18th February.)
So to sum up I believe INPH is presenting an excellent buy opportunity, provided that the stock breaks above the narrow trading range (which may take a few weeks). That's all I have for now. Don't forget to subscribe for feeds. Have a great weekend!
).